stockmarketproxy
/
XENENasdaqSEC EDGAREDGAR

Xenon Pharmaceuticals Inc.

Pharmaceutical Preparations·BURNABY·FY end 12/31·CIK 1582313
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue——————
Gross Profit——————
Operating Income-$373.1M-$279.3M-$214.1M-$129.1M-$79.0M
Net Income-$345.9M-$234.3M-$182.4M-$125.4M-$78.9M
Operating CF-$279.1M-$181.4M-$145.3M-$98.4M-$69.5M
Capex$799.0K$3.1M$5.6M$2.9M$2.0M
Free Cash Flow-$279.9M-$184.5M-$150.9M-$101.3M-$71.6M
Buybacks——————
Dividends——————
Gross Margin——————
Operating Margin——————
Net Margin——————
FCF Margin——————
R&D / Revenue——————
Effective Tax-0.3%1.7%0.2%-0.1%0.0%
Debt / Equity——————
Buybacks / FCF——————

Peer comparison

Pharmaceutical Preparations · 5 peers
CEO Pay Ratio
XENE
37:1
ROIV
518:1
AXSM
23:1
COGT
95:1
PFE
277:1
ABT
166:1
CEO total comp
XENE
$9M
ROIV
$163M
AXSM
$34M
COGT
$28M
PFE
$28M
ABT
$24M
Net Margin
XENE
—
ROIV
-592.0%
AXSM
-28.7%
COGT
—
PFE
12.4%
ABT
14.7%